Truist Financial Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today. The company’s shares closed yesterday at $0.51.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Germino covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Sangamo Biosciences, and Insmed. According to TipRanks, Germino has an average return of 37.2% and a 56.36% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $4.10 average price target, a 697.98% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.

The company has a one-year high of $3.18 and a one-year low of $0.30. Currently, Sangamo Biosciences has an average volume of 6.98M.